Fogelson

Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that target the chromatin regulatory system. Through its proprietary Gene Traffic Control platform, the company develops small molecule medicines designed to regulate gene expression by targeting the BAF complex and other chromatin remodeling machinery. Their approach focuses on addressing dependencies in cancer cells, particularly in genetically defined patient populations with mutations in chromatin regulatory genes. The company's pipeline includes both enzymatic inhibitors and protein degraders aimed at high-value targets in oncology.